National Health (Listed drugs on F1 or F2) Amendment Determination 2019 (No. 9) (PB 81 of 2019) (Cth)

PB 81 of 2019

National Health (Listed drugs on F1 or F2) Amendment Determination 2019 (No. 9)

National Health Act 1953

I, THEA DANIEL, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health, make this determination under subsection 85AB(1) of the National Health Act 1953.

Dated              30 September 2019

THEA DANIEL

Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Department of Health

Part 1         Preliminary

1. Name of Determination

(1)   This Determination is the National Health (Listed drugs on F1 or F2) Amendment Determination 2019 (No. 9).

(2)   This Determination may also be cited as PB 81 of 2019.

1. Commencement

This Determination commences on 1 October 2019.

1. Amendment of National Health (Listed drugs on F1 or F2) Determination 2010

Schedule 1 amends the National Health (Listed drugs on F1 or F2) Determination 2010 (PB 93 of 2010).

Schedule 1             Amendments

(Section 3)

[1]     Schedule 1, after item dealing with Apraclonidine

Insert

Aprepitant

[2]     Schedule 1, after item dealing with Bevacizumab

Omit

Biperiden

[3]     Schedule 1, after item dealing with Insulin detemir

Omit

Insulin glargine

[4]     Schedule 1, after item dealing with Ritonavir

Omit

Rituximab

[5]     Schedule 1, after item dealing with Tapentadol

Insert

Teduglutide

[6]     Schedule 2, after item dealing with Flutamide

Omit

Fluticasone

Fluticasone with Salmeterol

Insert

Fluticasone propionate

Fluticasone propionate with salmeterol

[7]     Schedule 2, after item dealing with Infliximab

Insert

Insulin glargine

[8]     Schedule 2, after item dealing with Risperidone

Insert

Rituximab